GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Meningococcal vaccine GSK134612
- First Posted Date
- 2007-05-09
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 385
- Registration Number
- NCT00471081
- Locations
- πΊπΈ
GSK Investigational Site, Amarillo, Texas, United States
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
- Conditions
- Neoplasms, Prostate
- Interventions
- First Posted Date
- 2007-05-08
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 127
- Registration Number
- NCT00470834
- Locations
- π¨π¦
GSK Investigational Site, Quebec, Canada
A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder
- Conditions
- Social Phobia
- Interventions
- Drug: Placebo treatment during 8 weeksDrug: Paroxetine treatment during 8 weeks
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT00470483
- Locations
- πͺπΈ
GSK Investigational Site, Barcelona, Spain
Comparison Of Two Tablet Formulations Of SB-568859
- Conditions
- Atherosclerosis
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT00470145
- Locations
- πΊπΈ
GSK Investigational Site, Buffalo, New York, United States
Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 46
- Registration Number
- NCT00469378
- Locations
- πΈπͺ
GSK Investigational Site, UmeΓ₯, Sweden
Safety, Blood Levels and Effects of GW642444
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: GW642444M for 14 days
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00469040
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: RSG XR
- First Posted Date
- 2007-05-03
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT00468897
- Locations
- π©πͺ
GSK Investigational Site, Neuss, Nordrhein-Westfalen, Germany
Study of Safety, Blood Levels and Brain Receptor Occupancy of GSK598809 Using PET Imaging in Health Males.
- Conditions
- Healthy Subjects
- First Posted Date
- 2007-05-03
- Last Posted Date
- 2010-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT00468806
- Locations
- π¨π¦
GSK Investigational Site, Toronto, Ontario, Canada
Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.
- Conditions
- Osteoporosis
- First Posted Date
- 2007-05-03
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT00468689
- Locations
- πΊπΈ
GSK Investigational Site, Baltimore, Maryland, United States
COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine
- Conditions
- Infections, Streptococcal
- Interventions
- Biological: Pneumococcal conjugate vaccine GSK1024850ABiological: HavrixBiological: Engerix-BBiological: Infanrix hexaBiological: GSK Biologicals' DTPa-IPV/Hib vaccine
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23802
- Registration Number
- NCT00466947
- Locations
- π΅π¦
GSK Investigational Site, Panama, Panama